Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heart Test Laboratories, Inc. ( (HSCS) ) just unveiled an update.
HeartSciences, Inc. has been actively involved in a Regulation A offering, which was qualified by the SEC on March 10, 2025, to raise up to $15 million through the sale of units comprising Series D Preferred Stock and warrants. As of August 22, 2025, the company has raised $5.2 million, with a significant portion of preferred stock being converted into common stock. Additionally, HeartSciences has executed a debt exchange, converting $1,655,000 of an unsecured promissory note into common stock, resulting in a total of 2,535,066 shares of common stock outstanding. These financial maneuvers reflect the company’s strategic efforts to strengthen its capital structure and enhance its market positioning.
The most recent analyst rating on (HSCS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.
Spark’s Take on HSCS Stock
According to Spark, TipRanks’ AI Analyst, HSCS is a Neutral.
Heart Test Laboratories, Inc. faces significant financial challenges, which heavily impact its overall stock score. Despite positive corporate events, such as FDA designation and patent acquisition, these are overshadowed by poor financial performance and valuation metrics. Technical analysis provides mixed signals, contributing to a moderate overall score.
To see Spark’s full report on HSCS stock, click here.
More about Heart Test Laboratories, Inc.
Average Trading Volume: 120,268
Technical Sentiment Signal: Sell
Current Market Cap: $8.06M
Learn more about HSCS stock on TipRanks’ Stock Analysis page.